Pay in 4 interest-free payments of $28.75 Learn more
Ships within 48 hours · Estimated delivery Jul 28 - Aug 2
at hydroxylation sites in the oxygen-dependent degradation domain (ODDD)
Activation of the pseudokinase MLKL unleashes the four-helix bundle domain to induce membrane localization and necroptotic cell death
Formula: C24H26BrN3O3
PubMed PMID: 22574676
BMS-927711 asvir diacetone at hydroxylation sites in theRimegepant, also known as BMS 927711 and BHV 3000, is a potent, selective, competitive, and orally active calcitonin gene related peptide (CGRP) antagonist in clinical trials for treating migraines. Rimegepant has shown in vivo efficacy without vasoconstriction effect. BMS 927711 is superior to placebo at several different doses (75 mg, 150 mg, and 300 mg) and has an excellent tolerability profile. Product information CAS Number: 1289023 67 1
US$ 1409.31
US$ 70.69
US$ 10451.34
US$ 21159.79